These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 8276049)
1. Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. Krähenbühl S; Grass P; Surve A; Kutz K; Reichen J Eur J Clin Pharmacol; 1993; 45(3):247-53. PubMed ID: 8276049 [TBL] [Abstract][Full Text] [Related]
2. Spirapril: pharmacokinetic properties and drug interactions. Grass P; Gerbeau C; Kutz K Blood Press Suppl; 1994; 2():7-13. PubMed ID: 8061850 [TBL] [Abstract][Full Text] [Related]
3. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? van den Meiracker AH; Man in 't Veld AJ; Admiraal PJ; Ritsema van Eck HJ; Boomsma F; Derkx FH; Schalekamp MA J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of spirapril in mild-to-moderate hypertension. Hayduk K; Kraul H J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 1():S19-23. PubMed ID: 10499560 [TBL] [Abstract][Full Text] [Related]
5. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Noble S; Sorkin EM Drugs; 1995 May; 49(5):750-66. PubMed ID: 7601014 [TBL] [Abstract][Full Text] [Related]
6. The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure. van den Broek SA; van Bruggen A; de Graeff PA; Hillege H; van Gilst WH; Wesseling H; Lie KI J Cardiovasc Pharmacol; 1991 Oct; 18(4):614-21. PubMed ID: 1724540 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. Hayes PC; Plevris JN; Bouchier IA J Hum Hypertens; 1989 Jun; 3 Suppl 1():153-8. PubMed ID: 2550638 [TBL] [Abstract][Full Text] [Related]
8. Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide. A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets. Schürer M; Erb K; Junge K; Schäfer HF; Schulz HU; Amschler S; Krupp S; Hermann R Arzneimittelforschung; 2003; 53(6):414-9. PubMed ID: 12872612 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Stein G; Sierakowski B; Grass P; Haufe CC; Jansa U; Weidinger G Blood Press Suppl; 1994; 2():47-53. PubMed ID: 8061846 [TBL] [Abstract][Full Text] [Related]
10. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor. van den Broek SA; de Graeff PA; Smit AJ; Girbes AR; Journée ; van Gilst WH; Hillege H; van Veldhuisen DJ; Wesseling H; Lie KI J Cardiovasc Pharmacol; 1995 Jan; 25(1):105-12. PubMed ID: 7723338 [TBL] [Abstract][Full Text] [Related]
11. Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. Shohat J; Wittenberg C; Erman A; Rosenfeld J; Boner G Scand J Urol Nephrol; 1999 Feb; 33(1):57-62. PubMed ID: 10100366 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. Bellissant E; Chau NP; Thuillez C; Gerbeau C; Richard C; Giudicelli JF J Cardiovasc Pharmacol; 1997 Aug; 30(2):253-60. PubMed ID: 9269955 [TBL] [Abstract][Full Text] [Related]
14. Effects of acute and chronic angiotensin converting enzyme inhibition by spirapril on cardiovascular regulation in essential hypertensive patients. Assessment by spectral analysis and haemodynamic measurements. Veerman DP; Douma CE; Jacobs MC; Thien T; Van Montfrans GA Br J Clin Pharmacol; 1996 Jan; 41(1):49-56. PubMed ID: 8824693 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme inhibitors: spirapril and related compounds. Smith EM; Swiss GF; Neustadt BR; McNamara P; Gold EH; Sybertz EJ; Baum T J Med Chem; 1989 Jul; 32(7):1600-6. PubMed ID: 2544729 [TBL] [Abstract][Full Text] [Related]
16. ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril. Jardine AG; Elliott HL J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 1():S31-4. PubMed ID: 10499562 [TBL] [Abstract][Full Text] [Related]
17. Digoxin pharmacokinetics and spirapril, a new ace inhibitor. Johnson BF; Wilson J; Johnson J; Flemming J J Clin Pharmacol; 1991 Jun; 31(6):527-30. PubMed ID: 1880218 [TBL] [Abstract][Full Text] [Related]
18. Cough induced activity of spirapril in rats. Kamei J; Hitosugi H; Kasuya Y Gen Pharmacol; 1993 Nov; 24(6):1443-5. PubMed ID: 8112517 [TBL] [Abstract][Full Text] [Related]
19. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril]. Haufe CC; Sierakowski B; Jansa U; Stein G Med Klin (Munich); 1994 Aug; 89(8):416-20. PubMed ID: 7968874 [TBL] [Abstract][Full Text] [Related]